CommentTowards a neuroimaging biomarker for amyotrophic lateral sclerosis
References (5)
- et al.
Biomarkers in amyotrophic lateral sclerosis
Lancet Neurol
(2009) - et al.
EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases
Eur J Neurol
(2010)
There are more references available in the full text version of this article.
Cited by (139)
Cortical and subcortical grey matter atrophy in Amyotrophic Lateral Sclerosis correlates with measures of disease accumulation independent of disease aggressiveness
2022, NeuroImage: ClinicalCitation Excerpt :Therefore, reliable biomarkers are needed that allow continuous and objective assessment of ALS pathology and progression. The opportunity of neuroimaging to support diagnostics, staging, and therapeutic monitoring in ALS, led to international joined efforts, notably the Neuroimaging Society in Amyotrophic Lateral Sclerosis (NiSALS) (Turner et al., 2011). Nevertheless, discrepancies remain between the measurements derived from Magnetic Resonance Imaging (MRI) and the individual ALS disease course (Steinbach et al., 2018; Verstraete et al., 2015).
Explainable models of disease progression in ALS: Learning from longitudinal clinical data with recurrent neural networks and deep model explanation
2021, Computer Methods and Programs in Biomedicine UpdateA proposal for new diagnostic criteria for ALS
2020, Clinical NeurophysiologySlow, slurred speech as an initial complaint in amyotrophic lateral sclerosis
2019, Auris Nasus Larynx
Copyright © 2011 Elsevier Ltd. All rights reserved.